BIO Quote, Financials, Valuation and Earnings

Avantor has a net margin of -107.24% compared to Bio-Rad Laboratories's net margin of 29.67%. Bio-Rad Laboratories's return on equity of -23.87% beat Avantor's return on equity of 12.92%.

Bio-Rad Laboratories has a consensus price target of $353.17, signalling upside risk potential of 45.56%. On the other hand Avantor has an analysts' consensus of $19.43 which suggests that it could grow by 53.74%. Given that Avantor has higher upside potential than Bio-Rad Laboratories, analysts believe Avantor is more attractive than Bio-Rad Laboratories.

Bio-Rad Laboratories has a beta of 1.119, which suggesting that the stock is 11.924% more volatile than S&P 500. In comparison Avantor has a beta of 1.236, suggesting its more volatile than the S&P 500 by 23.603%.

Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avantor offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. Avantor pays out -- of its earnings as a dividend.

Bio-Rad Laboratories quarterly revenues are $667.5M, which are smaller than Avantor quarterly revenues of $1.7B. Bio-Rad Laboratories's net income of -$715.8M is lower than Avantor's net income of $500.4M. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while Avantor's PE ratio is 12.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 2.67x versus 1.30x for Avantor. Usually stocks with elevated PS ratios are considered overvalued.

Azenta has a net margin of -107.24% compared to Bio-Rad Laboratories's net margin of -9.04%. Bio-Rad Laboratories's return on equity of -23.87% beat Azenta's return on equity of -7.97%.

Bio-Rad Laboratories has a consensus price target of $353.17, signalling upside risk potential of 45.56%. On the other hand Azenta has an analysts' consensus of $51.60 which suggests that it could grow by 93.04%. Given that Azenta has higher upside potential than Bio-Rad Laboratories, analysts believe Azenta is more attractive than Bio-Rad Laboratories.

Bio-Rad Laboratories has a beta of 1.119, which suggesting that the stock is 11.924% more volatile than S&P 500. In comparison Azenta has a beta of 1.660, suggesting its more volatile than the S&P 500 by 66.003%.

Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Azenta offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. Azenta pays out -- of its earnings as a dividend.

Bio-Rad Laboratories quarterly revenues are $667.5M, which are larger than Azenta quarterly revenues of $147.5M. Bio-Rad Laboratories's net income of -$715.8M is lower than Azenta's net income of -$13.3M. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while Azenta's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 2.67x versus 2.08x for Azenta. Usually stocks with elevated PS ratios are considered overvalued.

Bruker has a net margin of -107.24% compared to Bio-Rad Laboratories's net margin of 1.4%. Bio-Rad Laboratories's return on equity of -23.87% beat Bruker's return on equity of 6.78%.

Bio-Rad Laboratories has a consensus price target of $353.17, signalling upside risk potential of 45.56%. On the other hand Bruker has an analysts' consensus of $60.13 which suggests that it could grow by 53.9%. Given that Bruker has higher upside potential than Bio-Rad Laboratories, analysts believe Bruker is more attractive than Bio-Rad Laboratories.

Bio-Rad Laboratories has a beta of 1.119, which suggesting that the stock is 11.924% more volatile than S&P 500. In comparison Bruker has a beta of 1.184, suggesting its more volatile than the S&P 500 by 18.426%.

Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.51% to investors and pays a quarterly dividend of $0.05 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bio-Rad Laboratories quarterly revenues are $667.5M, which are smaller than Bruker quarterly revenues of $979.6M. Bio-Rad Laboratories's net income of -$715.8M is lower than Bruker's net income of $13.7M. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while Bruker's PE ratio is 51.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 2.67x versus 1.73x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of -107.24% compared to Bio-Rad Laboratories's net margin of 28.26%. Bio-Rad Laboratories's return on equity of -23.87% beat ResMed's return on equity of 25.76%.

Bio-Rad Laboratories has a consensus price target of $353.17, signalling upside risk potential of 45.56%. On the other hand ResMed has an analysts' consensus of $263.15 which suggests that it could grow by 11.56%. Given that Bio-Rad Laboratories has higher upside potential than ResMed, analysts believe Bio-Rad Laboratories is more attractive than ResMed.

Bio-Rad Laboratories has a beta of 1.119, which suggesting that the stock is 11.924% more volatile than S&P 500. In comparison ResMed has a beta of 0.755, suggesting its less volatile than the S&P 500 by 24.514%.

Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.88% to investors and pays a quarterly dividend of $0.53 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bio-Rad Laboratories quarterly revenues are $667.5M, which are smaller than ResMed quarterly revenues of $1.3B. Bio-Rad Laboratories's net income of -$715.8M is lower than ResMed's net income of $365M. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while ResMed's PE ratio is 26.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 2.67x versus 6.93x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.